Wednesday, January 25, 2012

HLA and pharmacogenetics : a quick summary

  • HLA-B*13:01 (present in about 2 to 20% of Chinese persons, 1.5% of Japanese persons, 1 to 12% of Indians, and 2 to 4% of Southeast Asians but is largely absent in Europeans and Africans) is associated with the development of the dapsone hypersensitivity syndrome among patients with leprosy (OR 20.5) (ref)
  • HLA-B*15:02/A*31:01 induces fatal skin reactions (Stevens-Johnson syndrome or toxic epidermal necrolysis) to carbamazepine and phenytoin/fosphenytoin in 10% (ref)
  • HLA-B*57:01 induces fatal hypersensitivity reactions to abacavir in 5-8% (ref) and liver injury due to flucloxacillin (ref)
  • HLA-B*58:01 induces  fatal skin reactions (Stevens-Johnson syndrome or toxic epidermal necrolysis) to allopurinol (ref)
  • HLA-C*04:01 increase the risk for Stevens-Johnson syndrome (OR = 17.5) and all hypersensitivity phenotypes (OR = 2.6) to nevirapine in 2.6% Malawian HIV patients (ref)
  • HLA-DRB1*07 and DQA1*02 induces reaction to ximelagatran in 5-7% (ref)
  • HLA-DRB1*07:01 induces a a higher incidence of hypersensitivity (OR = 1.64) and anti-asparaginase antibodies (OR = 2.92) (ref)
  • HLA-B*35:05 induces benznidazole related cutaneous reaction (45.5% vs 15.4%, P = .033) (ref)

Print this post

No comments:

Post a Comment